CD274 and diffuse large B-cell lymphoma: Our study suggests that targeting the PD-1/PD-L1 pathway with inhibitors may be an effective strategy for this challenging subset of DLBCL, especially given the generally well-tolerated nature of the treatment regimen, with no serious adverse events reported.